Skip to content

Investigations

Document-led investigations, audits, records, leaks and evidence trails.

Evidence analysis

Opinion/decision on a Paediatric investigation plan (PIP): Mounjaro, tirzepatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: EMA/PE/0000245851

Investigations into Paediatric Use of Tirzepatide (Mounjaro): EMA PIP Modification Decision This dossier evaluates the European Medicines Agency (EMA) decision dated 11 July 2025 regarding the modification of an agreed paediatric investigation plan (PIP) for tirzepatide, marketed as…

Read →

Evidence analysis

Opinion/decision on a Paediatric investigation plan (PIP): Exblifep, Enmetazobactam,cefepime, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations;Infectious diseases, PIP number: EMA/PE/0000247019

Investigations into the Paediatric Investigation Plan for Exblifep (Enmetazobactam / Cefepime) This dossier reviews publicly available information regarding a modification to a Paediatric Investigation Plan (PIP) concerning the combination drug Exblifep, which contains enmetazobactam and cefepime, intended for…

Read →

Evidence analysis

FBI Cybercrime Operation Nets Nine Arrests in Nigeria

Investigations into FBI Cybercrime Operation and Arrests in Nigeria What is established On October 26, 2026, the U.S. Federal Bureau of Investigation (FBI) announced the arrest of nine individuals in Nigeria as part of an international operation targeting…

Read →

Source briefing

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0169/2024

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP…

Read →

Source briefing

Opinion/decision on a Paediatric investigation plan (PIP): Nilemdo, bempedoic acid (ETC-1002), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000238109

Opinion/decision on a Paediatric investigation plan (PIP): Nilemdo, bempedoic acid (ETC-1002), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000238109

Read →